Trade IMTX stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Immatics N.V. (IMTX) is trading at US$5.95, down 2.46% today as of Nov 19, 16:00 EST. The company has a market capitalisation of US$929.44M. Over the past 52 weeks, IMTX has traded between US$5.83 and US$12.41. On Syfe you can trade IMTX with $0 commission and add it to your watchlist.
| Previous close | US$6.10 |
|---|---|
| Market cap | US$929.44M |
| 52-week range | US$5.83 – US$12.41 |
| Volume | 985.36K |
| Exchange | US |
Immatics N.V.
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline includes adoptive cell therapy and TCR Bispecifics. The company was founded on March 10, 2020, and is headquartered in Tuebingen, Germany.
Year: 2020
Stifel Initiates Immatics at Buy With $15 Price Target
Oct 14, 11:27 AM · MT Newswires
Sector Update: Healthcare Stocks Advance Tuesday Afternoon
Aug 25, 5:38 PM · MT Newswires
Immatics N.V. (IMTX) stock is trading at US$5.95, -2.46% from the previous close of US$6.10.
The market cap for Immatics N.V. (IMTX) stock is approximately US$929.44M.
The 52-week high for Immatics N.V. (IMTX) stock is US$12.41.
The 52-week low for Immatics N.V. (IMTX) stock is US$5.83.
Immatics N.V. (IMTX) does not currently pay a dividend.
Stay on top of IMTX
Price moves, news and earnings — straight to your inbox.
Snapshot
Popular Stocks in Singapore